Cyclic peptide-based nanostructures as efficient siRNA carriers (2018)
Sequence: Cyclo[WWGGGRRRRGGG]
| Experiment Id | EXP001459 |
|---|---|
| Paper | Cyclic peptide-based nanostructures as efficient siRNA carriers |
| Peptide | CP III |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | Uptake: 30 µM (FACS) or ~8 µM (confocal). Knockdown: 24 µM. |
| Rna Concentration | Uptake: 200 nM (FACS) or ~80 nM (confocal). Knockdown: 600 nM. |
| Mixing Ratio | Confocal: 0.04 nmol FAM-siRNA + 4 nmol peptide in 500 µL DMEM, 30 min complexation. FACS: 200 nM FAM-siRNA + 30 µM peptide in Opti-MEM, 30 min. Western blot: 24 µM peptide + 600 nM GAPDH siRNA in 500 µL serum-free DMEM, 30 min; incubate cells 3 h then add complete media and culture 48 h. |
| Formulation Format | Self-assembled cyclic peptide nanostructures / peptide–siRNA nanocomplexes (noncovalent) |
| Formulation Components | CP III + GAPDH siRNA (FAM-labeled for uptake; unlabeled for knockdown) |
| Size Nm | 238.50 |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HCT116 human colon cancer cells |
| Animal Model | |
| Administration Route | |
| Output Type | Uptake (confocal microscopy + flow cytometry) and functional gene silencing (GAPDH protein by Western blot) |
| Output Value | 2.4 |
| Output Units | |
| Output Notes | Moderate uptake by confocal microscopy and FACS (55.4% FAM-siRNA positive vs 2.3% siRNA alone). Significant GAPDH protein knockdown (~2.4-fold vs control), comparable to lipofectamine. |
| Toxicity Notes | Cyclic peptides showed >90% viability at 10 µM (24 h). siRNA/peptide complexes showed no significant cytotoxicity except CP I showed some cytotoxicity relative to other complexes; lipofectamine 2000 showed significant cytotoxicity. |
| Curation Notes |